Enterprise Value
482.7M
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
2.36%
Insider Ownership
0.19%
Institutional Own.
34.47%
Qtr Updated
09/30/22
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
FOTIVDA (Tivozanib) (VEGFR 123 TKI) Details Kidney cancer, Carcinoma , Genetic disorder, Rare genetic disease, Renal cell carcinoma | Approved Quarterly sales | |
FOTIVDA (tivo) + OPDIVO (nivolumab) Details Solid tumor/s, Renal cell carcinoma, Cancer | Phase 3 Update | |
Ficlatuzumab (HGF MAb) Details Head and neck cancer, Head and neck squamous cell carcinoma | Phase 3 Initiation | |
Tivozanib (FOTIVDA®) + IMFINZI® (durvalumab) Details HCC (Hepatocellular Carcinoma) (Untreated Metastatic) | Phase 1/2 Data readout |